In November 2017, it was announced that Lyrpro Biosciences had been acquired by Cerenis Therapeutics and will operate as a subsiduary to that entitity. Lypro Biosciences Inc is a biotechnology venture initially grounded in research activities conducted at Childrenâs Hospital Oakland Research Institute and University of California, San Francisco. The firm is a specialty biopharma company whose technology addresses the adverse effects arising from the insoluble nature of certain hydrophobic drugs. Lyproâs proprietary technology is based on lipid-based targetable, self-assembling, Nanodisksâ¢. Incorporating drugs into the highly stable and water-soluble Nanodisks⢠holds the promise of increased efficacy, lower doses, and reduced incidence and severity of side effects compared to current formulations. Lypro Biosciences has proof-of-concept data with Amphotericin-B, a highly effective, but highly toxic system fungal drug, in which the Lypro NanoDisks outperform both the native form of the drug and a liposomal formulation in efficacy and/or toxicity. Lyproâs pipeline includes NanoDisks loaded with off-patent compounds, targeted compounds and research reagents. The firm has programs underway in cancer, infectious diseases, imaging and neurosciences. The NanoDisk technology has been applied to the agricultur
